Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT)
| Autor: | Peter H. Wiernik, Stuart R. Lipsitz, Al B. Benson, Avi I. Einzig |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male medicine.medical_specialty Neutropenia Paclitaxel medicine.medical_treatment Adenocarcinoma Gastroenterology chemistry.chemical_compound Internal medicine medicine Humans Upper gastrointestinal Pharmacology (medical) Infusions Intravenous Aged Gastrointestinal Neoplasms Pharmacology Chemotherapy business.industry Stomach Middle Aged medicine.disease Antineoplastic Agents Phytogenic Surgery Clinical trial medicine.anatomical_structure Oncology chemistry Toxicity Female business |
| Zdroj: | Investigational New Drugs. 13:223-227 |
| ISSN: | 1573-0646 0167-6997 |
| DOI: | 10.1007/bf00873804 |
| Popis: | Taxol was administered as a 24-hour continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three were eligible and were evaluated for toxicity and twenty-two were assessable for response. There was one partial response (4.5%) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of the UGIT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink